CABA
Price
$1.45Alerts
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
Capitalization
220.41M
127 days until earnings call
Intraday BUY SELL Signals
OKUR
Price
$3.36Alerts
Change
-$0.02 (-0.59%)
Updated
Nov 11 closing price
Capitalization
116.02M
126 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CABA vs OKUR

CABA vs OKUR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CABA vs. OKUR commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a Hold and OKUR is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CABA with price predictions
Nov 10, 2026

CABA's RSI Oscillator ascending out of oversold territory

The RSI Indicator for CABA moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 22 of the 25 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where CABA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for CABA just turned positive on October 22, 2026. Looking at past instances where CABA's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.

Following a +17.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 218 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CABA as a result. In 76 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CABA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.047) is normal, around the industry mean (3.498). P/E Ratio (-0.942) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for OKUR with price predictions
Nov 10, 2026

OKUR in upward trend: price rose above 50-day moving average on November 06, 2026

OKUR moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 18 of 18 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on OKUR as a result. In 24 of 29 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for OKUR just turned positive on October 19, 2026. Looking at past instances where OKUR's MACD turned positive, the stock continued to rise in 14 of 16 cases over the following month. The odds of a continued upward trend are 88%.

Following a +18.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where OKUR advanced for three days, in 61 of 78 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OKUR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

OKUR broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for OKUR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.674) is normal, around the industry mean (3.498). P/E Ratio (-0.946) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. OKUR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OKUR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
CABA: Fundamental Ratings
CABA
OUTLOOK RATING
1..100
7
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
86
P/E GROWTH RATING
1..100
9
SEASONALITY SCORE
1..100
28

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CABAOKUR
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (CABA: $1.45 vs. OKUR: $3.38)
Brand notoriety: CABA and OKUR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CABA: 68% vs. OKUR: 60%
Market capitalization -- CABA: $220.41M vs. OKUR: $116.02M
CABA [@Biotechnology] is valued at $220.41M. OKUR’s [@Biotechnology] market capitalization is $116.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CABA’s FA Score shows that 1 FA rating(s) are green while OKUR’s FA Score has 1 green FA rating(s).

  • CABA’s FA Score: 1 green, 4 red.
  • OKUR’s FA Score: 1 green, 4 red.
According to our system of comparison, OKUR is a better buy in the long-term than CABA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CABA’s TA Score shows that 5 TA indicator(s) are bullish while OKUR’s TA Score has 4 bullish TA indicator(s).

  • CABA’s TA Score: 5 bullish, 3 bearish.
  • OKUR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CABA is a better buy in the short-term than OKUR.

Price Growth

CABA (@Biotechnology) experienced а +2.11% price change this week, while OKUR (@Biotechnology) price change was +35.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

CABA is expected to report earnings on Mar 18, 2027.

OKUR is expected to report earnings on Mar 17, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CABA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABA has been loosely correlated with AURA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
-3.33%
AURA - CABA
49%
Loosely correlated
-0.13%
EDIT - CABA
49%
Loosely correlated
-8.91%
VIR - CABA
47%
Loosely correlated
-3.63%
NCEL - CABA
47%
Loosely correlated
+4.00%
FATE - CABA
47%
Loosely correlated
-8.76%
More

OKUR and

Correlation & Price change

A.I.dvisor indicates that over the last year, OKUR has been loosely correlated with ELDN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if OKUR jumps, then ELDN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OKUR
1D Price
Change %
OKUR100%
+6.11%
ELDN - OKUR
34%
Loosely correlated
-3.83%
MGX - OKUR
32%
Poorly correlated
-3.01%
SGMT - OKUR
32%
Poorly correlated
+0.55%
CABA - OKUR
32%
Poorly correlated
-3.33%
IDYA - OKUR
32%
Poorly correlated
-0.87%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VGRO23.620.36
+1.53%
Virtus Silvant Growth Opportunities ETF (VGRO)
NURE32.760.11
+0.32%
Nuveen Short-Term REIT ETF (NURE)
CAIQ25.24N/A
N/A
Calamos Nasdaq Autocallable Income ETF
RGT15.10-0.01
-0.07%
Royce Global Value Trust
USA6.05-0.01
-0.17%
Liberty All-Star Equity Fund